EGFR L858R in advanced NSCLC: osimertinib 1L is standard (FLAURA); L858R historically sho...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-EGFR-L858R-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-EGFR-MUTATION |
|---|---|
| Variant | L858R |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | osimertinib monotherapy, osimertinib + pemetrexed/platinum (FLAURA2), amivantamab + lazertinib (MARIPOSA) |
| Evidence summary | EGFR L858R in advanced NSCLC: osimertinib 1L is standard (FLAURA); L858R historically shows somewhat lower TKI response than exon 19 del, prompting interest in combination strategies (FLAURA2 chemo combo; MARIPOSA amivantamab+lazertinib). Adjuvant osimertinib indicated post resection (ADAURA). |
Notes
ESCAT IA. OncoKB Level 1. L858R+co-occurring TP53 mutation associates with shorter PFS — consider combination 1L for high-risk subset.
Used By
No reverse references found in the YAML corpus.